bioRxivMicrobiologyPreprint
Antimicrobial and Cytotoxic Lysolipins I-M Isolated from Streptomyces sp. P8-2B18
Manar M. MahmoudiD, Kah Yean LumiD, Yiwei LiuiD, Mikael Lenz StrubeiD, Gundela PescheliD, Luciano D. O. SouzaiD, Miriam A. RosenbaumiD, José M.A. MoreiraiD, Stewart Brian KirtoniD, Charlotte Held GotfredseniD, Ling DingiD
Abstract
Lysolipin I (1) is a highly bioactive xanthone with strong antibacterial and cytotoxic properties. Given the limited number of lysolipin analogues, discovery of new natural lysolipin derivatives is important for understanding their structure-activity relationships. A soil-derived Streptomyces sp. P8-2B18 harbors a putative lysolipin biosynthetic gene cluster and LC-MS based metabolomic analysis revealed the production of lysolipin I along with unreported analogues. Large-scale fermentation followed by isolation led to the discovery of four new analogues, lysolipins J-M (2- 5), the structures of which were elucidated by mass spectrometric and NMR spectroscopic data analyses. Lysolipin L features a five-membered lactam F ring, which was unprecedented in reported lysolipins. Lysolipin M has a novel skeleton, with an extra methyl (Me-36) and a glycosyl group replacing a 1,3-oxane ring in lysolipin I. While lysolipins I, J and K displayed strong activity against Staphylococcus aureus and Aspergillus flavus with MIC values ranging from 0.25 to 4 g/mL and lysolipin L showed only moderate activities, lysolipin M was inactive (>50 g/mL). Lysolipins I-K showed potent cytotoxic activity against prostate cancer cell lines LNCaP and C4-2B, with IC50 values in the submicromolar range. In contrast, lysolipin L exhibited no cytotoxicity and lysolipin M exhibited substantially reduced potency. Their broad, non-selective bioactivities restricted their applicability as therapeutic agents.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lunaemycins, new cyclic hexapeptide antibiotics from the cave moonmilk-dweller Streptomyces lunaelactis MM109
L. Martinet, A. Naome, … S. Rigali·bioRxiv·Dec 15, 2022
- New from old: discovery of the novel antibiotic actinomycin L in Streptomyces sp. MBT27
N. Machushynets, S. S. Elsayed, … G. P. van Wezel·bioRxiv·Oct 12, 2021
- In situ activation and heterologous production of a cryptic lantibiotic from a plant-ant derived Saccharopolyspora species
E. Vikeli, D. Widdick, … B. Wilkinson·bioRxiv·Aug 13, 2019
- Shared PKS modules in biosynthesis of synergistic laxaphycins
L. M. P. Heinilä, D. P. Fewer, … K. Sivonen·bioRxiv·May 29, 2020
- A phylogenetic and evolutionary analysis of antimycin biosynthesis
R. Joynt, R. F. Seipke·bioRxiv·Jul 15, 2017
- The fate of bacterial secondary metabolites in the rhizosphere: Streptomyces degrades and feeds on cyclic lipopeptides produced by competitors
A. Rigolet, A. Arguelles Arias, … M. Ongena·bioRxiv·Jul 27, 2023